| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Study of AT-752 in Patients With Dengue InfectionNCT05466240 | AVIR | Phase 2 | Terminated | 2023-01-19Actual |
| Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)NCT05466890 | PTN | Phase 2 | Active not recruiting | 2025-02-10Actual |
| Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 YearsNCT05468736 | Novavax | Phase 2, Phase 3 | Completed | 2024-01-16Actual |
| A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel ResectionNCT05470387 | Palisade Bio | Phase 3 | Terminated | 2023-03-06Actual |
| A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 InfectionNCT05472090 | Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | 2023-07-12Actual |
| A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in RemissionNCT05479058 | LKFT | Phase 3 | Terminated | 2023-10-09Actual |
| Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept StudyNCT05481736 | COMPASS Pathways | Phase 2 | Completed | 2024-11-18Actual |
| A Study of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaNCT05485987 | PTC Therapeutics | Phase 2 | Completed | 2024-08-29Actual |
| A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)NCT05490446 | AGIO | Phase 2 | Active not recruiting | 2026-03-17Actual |
| Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPCNCT05494697 | AIM | Phase 2 | Suspended | 2031-02Estimated |
| Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)NCT05494788 | CRDL | Phase 2 | Completed | 2024-06-15Actual |
| A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary DiseaseNCT05496374 | Spero Therapeutics | Phase 2 | Completed | 2024-10-08Actual |
| Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria FlaresNCT05496465 | SPRY | Phase 2 | Completed | 2024-02-29Actual |
| A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)NCT05500222 | MDGL | Phase 3 | Active not recruiting | 2026-12Estimated |
| Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 | CELC | Phase 3 | Active not recruiting | 2026-06-30Estimated |
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943 | Compass Therapeutics | Phase 2, Phase 3 | Active not recruiting | 2027-08-31Estimated |
| ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1NCT05507203 | ABVX | Phase 3 | Completed | 2025-06-24Actual |
| ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2NCT05507216 | ABVX | Phase 3 | Completed | 2025-06-24Actual |
| Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)NCT05509023 | QTTB | Phase 2 | Active not recruiting | 2024-12Estimated |
| Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic ArthritisNCT05511519 | ACRS | Phase 2 | Terminated | 2023-12-06Actual |
| A Study of CTX-009 in Adult Patients With Metastatic Colorectal CancerNCT05513742 | Compass Therapeutics | Phase 2 | Completed | 2025-05-15Actual |
| A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich AtaxiaNCT05515536 | PTC Therapeutics | Phase 3 | Active not recruiting | 2027-12-31Estimated |
| Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsyNCT05518578 | SUPN | Phase 2 | Recruiting | 2027-12-31Estimated |
| A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination VaccineNCT05519839 | Novavax | Phase 2 | Completed | 2023-07-25Actual |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton SyndromeNCT05521438 | Quoin Pharmaceuticals | Phase 2, Phase 3 | Active not recruiting | 2025-12-30Actual |
| An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseNCT05522387 | INMB | Phase 2 | Terminated | 2024-06-05Actual |
| Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum DisorderNCT05523895 | ACAD | Phase 2, Phase 3 | Completed | 2024-09-27Actual |
| Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810NCT05526066 | Arcturus Therapeutics, Inc. | Phase 2 | Terminated | 2024-10-31Actual |
| A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaNCT05529316 | AGEN | Phase 2 | Terminated | 2026-04-27Actual |
| A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseNCT05531656 | Cognition Therapeutics | Phase 2 | Active not recruiting | 2027-05-31Estimated |
Trial details
- Registry ID
- NCT05466240
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05466890
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05468736
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05470387
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05472090
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05479058
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05481736
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05485987
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05490446
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05494697
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05494788
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05496374
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05496465
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05500222
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05501886
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05506943
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05507203
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05507216
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05509023
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05511519
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05513742
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05515536
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05518578
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05519839
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05521438
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05522387
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05523895
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05526066
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05529316
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05531656
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.